UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

Cancer discovery, 2014-09, Vol.4 (9), p.1046-1061

2014

Volltextzugriff (PDF)

Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers

Clinical cancer research, 2010-07, Vol.16 (14), p.3548-3561

2010

Volltextzugriff (PDF)

ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy

Cancer research (Chicago, Ill.), 2002-10, Vol.62 (20), p.5749-5754

2002

Volltextzugriff (PDF)

Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic-Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104

Molecular cancer therapeutics, 2016-10, Vol.15 (10), p.2378-2387

2016

Volltextzugriff (PDF)

Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma

Molecular cancer therapeutics, 2019-05, Vol.18 (5), p.909-919

2019

Volltextzugriff (PDF)

Studies leading to the identification of ZD1839 (Iressa) : An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

Bioorganic & medicinal chemistry letters, 2001-07, Vol.11 (14), p.1911-1914

2001

Volltextzugriff (PDF)

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

Nature communications, 2019-05, Vol.10 (1), p.1-22, Article 2030

2019

Volltextzugriff (PDF)

Researcher or nurse? Difficulties of undertaking semi-structured interviews on sensitive topics

Nurse researcher, 2014-09, Vol.22 (1), p.27-31

Ashton, Susan

2014

Volltextzugriff (PDF)

Correlation of MRI Biomarkers with Tumor Necrosis in Hras5 Tumor Xenograft in Athymic Rats

Neoplasia (New York, N.Y.), 2007-05, Vol.9 (5), p.382-391

2007

Volltextzugriff (PDF)

Aminoimidazolylmethyluracil Analogues as Potent Inhibitors of Thymidine Phosphorylase and Their Bioreductive Nitroimidazolyl Prodrugs

Journal of medicinal chemistry, 2005-01, Vol.48 (2), p.392-402

2005

Volltextzugriff (PDF)

A novel in situ hydrophobic ion paring (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system

Journal of controlled release, 2016-05, Vol.229, p.106-119

2016

Volltextzugriff (PDF)

ZD6126: A novel small molecule vascular targeting agent

International journal of radiation oncology, biology, physics, 2002-12, Vol.54 (5), p.1497-1502

2002

Volltextzugriff (PDF)

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

Journal of medicinal chemistry, 2014-10, Vol.57 (20), p.8249-8267

2014

Volltextzugriff (PDF)

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

Science translational medicine, 2016-02, Vol.8 (325), p.325ra17

2016

Volltextzugriff (PDF)

End of life care: The experiences of advance care planning amongst family caregivers of people with advanced dementia – A qualitative study

Dementia (London, England), 2016-09, Vol.15 (5), p.958-975

2016

Volltextzugriff (PDF)

Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126

Microvascular research, 2006-03, Vol.71 (2), p.76-84

2006

Volltextzugriff (PDF)

Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma

Oncotarget, 2016-12, Vol.7 (52), p.86313-86325

2016

Volltextzugriff (PDF)

Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2‐specific antagonist is associated with reduced tumor growth

International journal of cancer, 2011-08, Vol.129 (4), p.847-858

2011

Volltextzugriff (PDF)

Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

Journal of medicinal chemistry, 2013-09, Vol.56 (17), p.7025-7048

2013

Volltextzugriff (PDF)

P111 Reaching out – gum in the general practice setting

Sexually transmitted infections, 2017-06, Vol.93 (Suppl 1), p.A53-A53

2017

Volltextzugriff (PDF)

Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles

Molecular cancer therapeutics, 2017-06, Vol.16 (6), p.1031-1040

2017

Volltextzugriff (PDF)

Abstract B212: Integrating the pre-clinical pharmacokinetic, pharmacodynamics, and efficacy data for AZD9291, an oral, irreversible inhibitor of EGFR activating (EGFRm+) and resistant (EGFRm+/T790M) mutations and an active metabolite to predict the human pharmacokinetics and potential efficacious dose in patients

Molecular cancer therapeutics, 2013-11, Vol.12 (11_Supplement), p.B212-B212

2013

Volltextzugriff (PDF)

Abstract 3102: AZD1152HQPA Accurin™ nanoparticles inhibit growth of diffuse large B-cell lymphomas and small cell lung cancer

Cancer research (Chicago, Ill.), 2015-08, Vol.75 (15_Supplement), p.3102-3102

2015

Volltextzugriff (PDF)

A novel in situ hydrophobic ion pairing (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system

Journal of controlled release, 2016-05, Vol.229, p.106-119

2016

Volltextzugriff (PDF)

1 – 25 von 254

Suche als RSS-Feed

Aktive Filter

KollektionOxford University Press Journals Current

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(229)
Mit Volltextzugriff
(211)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(155)
Life Sciences & Biomedicine
(120)
Humans
(88)
Female
(48)
Male
(44)
Animals
(36)
Biological And Medical Sciences
(27)
Middle Aged
(26)
Mice
(25)
Physical Sciences
(24)
Adult
(23)
Oncology
(22)
Medical Sciences
(21)
Social Sciences
(16)
Neurosciences
(15)
Science & Technology - Other Topics
(15)
Chemistry
(14)
Aged
(13)
Pharmacology & Pharmacy
(13)
Technology
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer

Vascular Endothelial Growth Factor Receptors VEGFR-2 and VEGFR-3 Are Localized Primarily to the Vasculature in Human Primary Solid Cancers

ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy

Irreversible Inhibition of EGFR: Modeling the Combined Pharmacokinetic-Pharmacodynamic Relationship of Osimertinib and Its Active Metabolite AZ5104

Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma

Studies leading to the identification of ZD1839 (Iressa) : An orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer

MEK1/2 inhibitor withdrawal reverses acquired resistance driven by BRAFV600E amplification whereas KRASG13D amplification promotes EMT-chemoresistance

Researcher or nurse? Difficulties of undertaking semi-structured interviews on sensitive topics

Correlation of MRI Biomarkers with Tumor Necrosis in Hras5 Tumor Xenograft in Athymic Rats

Aminoimidazolylmethyluracil Analogues as Potent Inhibitors of Thymidine Phosphorylase and Their Bioreductive Nitroimidazolyl Prodrugs

A novel in situ hydrophobic ion paring (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system

ZD6126: A novel small molecule vascular targeting agent

Discovery of a Potent and Selective EGFR Inhibitor (AZD9291) of Both Sensitizing and T790M Resistance Mutations That Spares the Wild Type Form of the Receptor

Aurora kinase inhibitor nanoparticles target tumors with favorable therapeutic index in vivo

End of life care: The experiences of advance care planning amongst family caregivers of people with advanced dementia – A qualitative study

Tumour overexpression of inducible nitric oxide synthase (iNOS) increases angiogenesis and may modulate the anti-tumour effects of the vascular disrupting agent ZD6126

Inhibition of oxidative phosphorylation suppresses the development of osimertinib resistance in a preclinical model of EGFR-driven lung adenocarcinoma

Cells Lacking the RB1 Tumor Suppressor Gene Are Hyperdependent on Aurora B Kinase for Survival

Inhibition of neutrophil infiltration into A549 lung tumors in vitro and in vivo using a CXCR2‐specific antagonist is associated with reduced tumor growth

Structure- and Reactivity-Based Development of Covalent Inhibitors of the Activating and Gatekeeper Mutant Forms of the Epidermal Growth Factor Receptor (EGFR)

P111 Reaching out – gum in the general practice setting

Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles

Abstract 3102: AZD1152HQPA Accurin™ nanoparticles inhibit growth of diffuse large B-cell lymphomas and small cell lung cancer

A novel in situ hydrophobic ion pairing (HIP) formulation strategy for clinical product selection of a nanoparticle drug delivery system

Aktive Filter

Suchergebnisse filtern